Immunoglobulin Market Trends

Immunoglobulin Market Trends

The rise in the occurrence of immunodeficiency disorders can be attributed to sedentary lifestyle habits, including the consumption of saturated fats, excessive salt and sweets, reduced physical activity, and high alcohol intake. Consequently, the escalating frequency of lifestyle-related illnesses such as obesity and conditions stemming from inadequate antibody production is set to expedite market expansion. For instance, as indicated by a report from the National Institute of Health, there exist over 200 distinct types of primary immune deficiency diseases (PIDDs), impacting roughly 500,000 individuals in the United States alone. Hence, the demand for immunoglobulin therapy is expected to surge in the foreseeable future due to the growing prevalence of both primary and acquired immunodeficiency ailments.
 

Immunoglobulin Market Restrain

The anticipated impediment to the growth of the market stems from the considerable expenses associated with this therapy. For instance, according to findings from the Children's Hospital of Philadelphia Research Institute, immunoglobulin replacement therapy (IRT) represents the standard of care for congenital agammaglobulinemia in the U.S. and other high-income countries. This therapy is administered either monthly through intravenous infusion or weekly/biweekly via subcutaneous infusion. While the treatment significantly reduces the occurrence of infections, it does not offer absolute prevention for all infections. Furthermore, the need for frequent infusions impacts the quality of life for patients. Moreover, the cost of IRT treatment falls within the range of USD 30,000 to USD 90,000 in the U.S. Consequently, the elevated treatment expenses are expected to act as a barrier to market demand.